Eilean Therapeutics Joins The Leukemia & Lymphoma Society’s Groundbreaking Beat AML® Master Clinical Trial

Beat AML is transforming treatment for people with acute myeloid leukemia through a collaborative targeted treatment approach New trial arm will evaluate lomonitinib, Eilean’s precision therapy designed to address AML treatment resistance DOVER, Del., June 11, 2024 /PRNewswire/ — Eilean…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.